Richard Eisenstadt
2022 - PharmAthene
In 2022, Richard Eisenstadt earned a total compensation of $619.7K as Chief Financial Officer at PharmAthene, a 64% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $170,000 |
|---|---|
| Salary | $426,635 |
| Other | $23,059 |
| Total | $619,694 |
Eisenstadt received $426.6K in salary, accounting for 69% of the total pay in 2022.
Eisenstadt also received $170K in non-equity incentive plan and $23.1K in other compensation.
Rankings
In 2022, Richard Eisenstadt's compensation ranked 3,980th out of 5,676 executives tracked by ExecPay. In other words, Eisenstadt earned more than 29.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,980 out of 5,676 | 30th |
Division Manufacturing | 2,249 out of 3,084 | 27th |
Major group Chemicals And Allied Products | 1,091 out of 1,399 | 22nd |
Industry group Drugs | 1,024 out of 1,300 | 21st |
Industry Pharmaceutical Preparations | 746 out of 942 | 21st |
Source: SEC filing on August 16, 2023.
Eisenstadt's colleagues
We found three more compensation records of executives who worked with Richard Eisenstadt at PharmAthene in 2022.
News
PharmAthene CEO Vipin Garg's 2022 pay rises 9% to $2.9M
August 16, 2023
PharmAthene CEO Vipin Garg's 2021 pay jumps 83% to $2.6M
August 16, 2022
AYTU BIOPHARMA CEO Joshua Disbrow's 2021 pay jumps 291% to $6.2M
April 7, 2022
Neos Therapeutics CEO Gerald McLaughlin's 2019 pay falls 56% to $1.4M
April 21, 2020
Neos Therapeutics CEO Gerald McLaughlin receives $3.2M in 2018
April 24, 2019